| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 04/07/2009 | US7514462 ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| 04/07/2009 | US7514456 Nicotinamide derivatives useful as p38 inhibitors |
| 04/07/2009 | US7514259 Derived from the neuroretina of the eye ex vivo and in vivo |
| 04/07/2009 | US7514098 Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| 04/07/2009 | US7514086 Peptide-based vaccine for influenza |
| 04/07/2009 | US7514084 isolated nonapeptide that bind to an human leukocyte antigen (HLA-A 0201) restricted T cell receptors with high affinity and induce a high cytotoxic T lymphocyte response, used for treating or preventing tumors and cancers |
| 04/07/2009 | CA2493633C Kinase inhibitors |
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2415890C N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/07/2009 | CA2413190C Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 04/07/2009 | CA2372384C Anti-inflammatory bioactive glass particulates |
| 04/07/2009 | CA2352503C Il-5 inhibiting 6-azauracil derivatives |
| 04/07/2009 | CA2117492C Bystander suppression of autoimmune diseases |
| 04/07/2009 | CA2080700C Enzymatic disinsertion of vitreous body |
| 04/02/2009 | WO2009042746A1 Novel antibodies |
| 04/02/2009 | WO2009042444A2 Methods and compounds for treating retinol-related diseases |
| 04/02/2009 | WO2009042395A1 Compositions comprising quinolone and methods for treating or controlling infections |
| 04/02/2009 | WO2009042377A1 Pharmacological adjunctive treatment associated with glaucoma filtration surgery |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041566A1 Preventive or remedy for posterior eye diseases containing quinazolinone derivative or quinoxaline derivative as the active ingredient |
| 04/02/2009 | WO2009041565A1 Quinazolinone derivative, and prophylactic or therapeutic agent for corneal/conjunctival disorder comprising quinazolinone derivative as active ingredient |
| 04/02/2009 | WO2009041521A1 Quinolone derivative |
| 04/02/2009 | WO2009040336A1 Antigen binding proteins |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009018333A3 Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| 04/02/2009 | US20090088472 Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient |
| 04/02/2009 | US20090087459 Methods for treating eye disorders |
| 04/02/2009 | US20090087458 Activatable recombinant neurotoxins |
| 04/02/2009 | US20090087443 Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
| 04/02/2009 | US20090087424 Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1 |
| 04/02/2009 | US20090087413 Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
| 04/02/2009 | CA2700481A1 Antigen binding proteins |
| 04/02/2009 | CA2700088A1 Quinolone derivative |
| 04/02/2009 | CA2699773A1 Methods and compounds for treating retinol-related diseases |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042503A1 Compound having acidic group which may be protected, and use thereof |
| 04/01/2009 | EP2042499A1 Salt of morpholine compound |
| 04/01/2009 | EP2042178A1 Ocular formulations comprising 5-chlorouracil and use thereof |
| 04/01/2009 | EP2041135A1 8-oxoadenine derivatives acting as modulators of tlr7 |
| 04/01/2009 | EP2041128A2 Substituted gamma lactams as therapeutic agents |
| 04/01/2009 | EP2040741A1 Hyaluronic acid and hyaluronidase in the enhancement of lens regeneration |
| 04/01/2009 | EP2040728A2 Fkbp-l and uses thereof |
| 04/01/2009 | EP2040721A1 Medicinal compositions containing honey |
| 04/01/2009 | EP2040706A2 Modulators of muscarinic receptors |
| 04/01/2009 | CN101400703A Domain antibody construct |
| 04/01/2009 | CN101400659A Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
| 04/01/2009 | CN101400377A Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
| 04/01/2009 | CN101400354A Aqueous composition |
| 04/01/2009 | CN101397343A VEGF receptor fusion protein and its use in preparation of medicament for treating eye disease |
| 04/01/2009 | CN101396533A Traditional Chinese medicine for treating acute catarrhal otitis media |
| 04/01/2009 | CN101396487A Manufacture method of powder for treating auricle erosion and pyorrhea for three days |
| 04/01/2009 | CN101396388A Extraction method of Jumi extract and preparation method of the Jumi preparation |
| 04/01/2009 | CN101396361A Medicine composition containing L-carnosine for suspending the development of the cataract |
| 04/01/2009 | CN101396339A Novel degradable lacrimal passage plug and preparation method thereof |
| 04/01/2009 | CN101396335A Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 04/01/2009 | CN101396333A Eye in-situ gel of chiral anti-glaucoma medicine L-3alpha alkyla acyloxy-6belta alkyla acyloxy tropane and preparation method thereof |
| 04/01/2009 | CN100473417C Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 03/31/2009 | US7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
| 03/31/2009 | US7511074 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke |
| 03/31/2009 | US7511073 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/31/2009 | US7511047 Kinase inhibitors |
| 03/31/2009 | CA2448602C Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/31/2009 | CA2417897C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 03/31/2009 | CA2339792C Opthalmic solution with tetracycline for topical treatment of dry eye disease |
| 03/31/2009 | CA2307285C Agent for prophylaxis and treatment of glaucoma |
| 03/31/2009 | CA2292549C Use of colchinol derivatives as vascular damaging agents |
| 03/31/2009 | CA2193597C Otic microbial combinations |
| 03/26/2009 | WO2009039356A1 Treatment methods with brimonidine |
| 03/26/2009 | WO2009038683A2 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 03/26/2009 | WO2009038243A1 Composition for treating retinopathy or glaucoma comprising thrombin derived peptides |
| 03/26/2009 | WO2009036656A1 Coumarin derivatives, preparation processes and uses thereof |
| 03/26/2009 | WO2009022897A3 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 03/26/2009 | WO2009007457A3 Compounds and methods for modulating rho gtpases |
| 03/26/2009 | WO2008137780A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| 03/26/2009 | WO2008116641A3 Oleyl phosphocholine |
| 03/26/2009 | WO2007092620A3 Stable formulations, and methods of their preparation and use |
| 03/26/2009 | US20090082860 Ocular Implants with Asymmetric Flexibility |
| 03/26/2009 | US20090082567 2,4-pyrimidinediamine compounds and their uses |
| 03/26/2009 | US20090082470 Stat3 inhibiting compositions and methods |
| 03/26/2009 | US20090082455 Therapeutic agent for ophthalmic disease |
| 03/26/2009 | US20090082381 Percutaneously Absorbable Ophthalmic Preparation |
| 03/26/2009 | US20090082369 Pyrrolo[2,3d]pyrimidine compositions and their use |
| 03/26/2009 | US20090082362 Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure |
| 03/26/2009 | US20090082338 Preventive or remedy for glaucoma |
| 03/26/2009 | US20090082321 Steroid containing drug delivery systems |
| 03/26/2009 | US20090081730 Activatable recombinant neurotoxins |
| 03/26/2009 | US20090081635 Modified heparinase iii and methods of sequencing therewith |
| 03/26/2009 | US20090081194 Compositions and methods for reducing risk of development, or severity, of inappropriate immune response in eyes |
| 03/26/2009 | US20090081187 Pharmacological vitreolysis |
| 03/26/2009 | US20090081159 Compositions and methods for detecting and treating ophthalmic disorders |
| 03/26/2009 | US20090081126 Novel fully human anti-VAP-1 monoclonal antibodies |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/26/2009 | CA2699292A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 03/25/2009 | EP2039700A2 Novel anti-inflammatory androstane derivatives |
| 03/25/2009 | EP2039361A2 Use of immunomodulatory compounds |
| 03/25/2009 | EP2037952A1 Vitreous administration of erythropoietin |
| 03/25/2009 | EP2037924A2 Bicyclic heteroaryl inhibitors of pde4 |
| 03/25/2009 | EP2000469A9 Acylaminopiperidine compound |